Bacillus subtilis KC1 prevents Mycoplasma gallisepticum-induced lung injury by enhancing intestinal Bifidobacterium animalis and regulating indole metabolism in chickens

Chen, Xueping; Ishfaq, Muhammad; Hu, Fangyuan; Zheng, Qin; Hu, Xiang; Jian, Wang; Huo, Nairui

doi:10.1016/j.psj.2023.102824

Cited by 3 publications

(1 citation statement)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistently, the positive effect of Lactobacillus rhamnosus GG in alcohol-associated liver disease (ALD) was associated with its bacterial AHR ligand-enriched exosome-like nanoparticles (ELNPs), which increased expression of Reg3 and Nrf2 thereby improving barrier function ( Gu et al., 2021b ). Additionally, Bacillus subtilis KC1 enhanced AHR activation thus alleviating lung injury ( Chen et al., 2023 ). Bifidobacterium longum CCFM1029 reshaped the gut microbial composition in atopic dermatitis patients, and activated the AHR-mediated immune response, alleviating related symptoms ( Fang et al., 2022 ).…”

Section: Future Prospectsmentioning

confidence: 99%

Activation of the aryl hydrocarbon receptor in inflammatory bowel disease: insights from gut microbiota

Hou,

Ma,

Qin

2023

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Inflammatory bowel disease (IBD) is a chronic inflammatory intestinal disease that affects more than 3.5 million people, with rising prevalence. It deeply affects patients’ daily life, increasing the burden on patients, families, and society. Presently, the etiology of IBD remains incompletely clarified, while emerging evidence has demonstrated that altered gut microbiota and decreased aryl hydrocarbon receptor (AHR) activity are closely associated with IBD. Furthermore, microbial metabolites are capable of AHR activation as AHR ligands, while the AHR, in turn, affects the microbiota through various pathways. In light of the complex connection among gut microbiota, the AHR, and IBD, it is urgent to review the latest research progress in this field. In this review, we describe the role of gut microbiota and AHR activation in IBD and discussed the crosstalk between gut microbiota and the AHR in the context of IBD. Taken as a whole, we propose new therapeutic strategies targeting the AHR–microbiota axis for IBD, even for other related diseases caused by AHR-microbiota dysbiosis.

show abstract

Section: Future Prospectsmentioning

confidence: 99%